Transmembrane Peptides for applications in biosensors: NB from influenza B. by Fischer W. B. et al.
Transmembrane Peptides for applications in biosensors:  
NB from influenza B. 
Fischer W. B., Pitkeathly M.1, Wallace B. A.2, Sansom M. S. P.3 
Department of Biochemistry, University of Oxford, Oxford OX1 3QU, UK  
Tel: +44 – 1865 – 275776 
wolfgang@bioch.ox.ac.uk         http://www2.bioch.ox.ac.uk/~wolfgang/ 
1Centre for Molecular Science, University of Oxford, Oxford, OX1 3QU, UK, 
2Laboratory of Molecular Biophysics, University of Oxford, Oxford OX1 3QU, UK. 
3Department of Crystallography, Birkbeck College, University of London, London, UK 
 
Abstract 
NB from influenza B is a short auxiliary protein 100 amino acids in length. It is believed to have a 
similar role in the virus life cycle to the channel forming protein M2 from influenza A. The latter 
channel can be blocked by amantadine. We have synthesized the putative transmembrane segment 
of NB: IRGS20 IIITICVSLI30 VILIVFGCIA40 KIFI (NB, Lee). Reconstituted in a lipid bilayer the peptide 
shows channel activity (Fischer et al. Biochemistry 39, 12708-12716 (2000)). In the presence of 
amantadine channel activity is lost reversibly. Channel activity per se and in the presence of 
amantadine is similar to the behaviour of the complete NB protein (Sunstrom et al. J. Membr. Biol. 
150, 127-132 (1996)). The synthetic transmembrane fragment resembles the characteristics of the 
intact NB protein. 
 
Introduction 
Biological lipid membranes separate the interior of a cell from the ‘out-side world’. Sub-cellular 
compartments are also separated by lipid membranes. The amphiphatic nature of the lipids 
assembles these molecules in such a way that a large hydrophobic barrier is created. The 
hydrophobic barrier prevents the flow of charged molecules across the membrane. However, to allow 
for a facilitated passage of ions or molecules from one side of the compartment to the other the lipid 
membrane is spanned by particular proteins adapted perfectly to the hydrophobic lipid environment. 
These proteins are called integral membrane proteins (here referred to as membrane proteins for 
simplicity). Some examples are: ATPases, G-protein coupled receptors, light harvesting membrane 
proteins, ion channels.  Approximately 30 – 40 % of the coding region of each organism’s genome 




Fig. 1: Cartoon of the channel protein NB from 
influenza B (red) in a lipid bilayer (green) (left) 
consisting of an extramembraneous (above the 
bilayer), a transmembraneous (TM) (within the 
bilayer), and a cytoplasmic (below the bilayer) 
segment. Two peptides are shown. In vivo 
more segments have to assemble to form a 
pore. Solely the TM segment of NB (NB 
peptide) in a lipid bilayer is shown on the right. 
Like bigger channels (e.g. nAChR) the viral ion 
channel forming protein has also to assemble 
to form functioning channels.  
date. From a medical point of view it is therefore not surprising that about half of the drugs currently 
available target membrane proteins [1]. Consequently there is an enormous demand for analytical 
techniques detecting protein-drug interactions for the screening of new drugs and there will be even 
so more in the future.  
There are a variety of options to initiate the transfer of information across the membrane e.g. by light, 
through ions, via hormones. For each option specific membrane proteins have evolved. For shuffling 
ions along the electrochemical gradient across the membrane the cells use ion channels. Ion 
channels form water filled pores across the lipid membrane (Fig. 1) which can, depending on the 
particular channel type, be opened on command (triggered by ligands or by an altered 
electrochemical gradient) or statistically. Also viruses, especially enveloped viruses use ion channels 
to survive. However, the length of these proteins is about five times less than that of ion channels 
found in cells. Thus, the viral channels represent miniaturized channel systems made by nature.  
 
Investigations on the potential use of ion channels in biosensor devices have been carried out for the 
last 15 years. The first report of the use of an ion channel, the glutamate receptor (a channel which is 
triggered by the ligand glutamate), was in 1990 [2]. The receptor was reconstituted in an artificial lipid 
membrane and signals were recorded electrically. Fig. 2 shows a cartoon of a sampling unit to apply 
the technique developed by Montal & Müller [3] (see figure legend for details). In another study a 
voltage dependent anion channel (VDAC) was transferred onto a platin surface and the results 
indicate that changes in the conductance behaviour are to be expected in such a measurement unit 
[4, 5]. Recently a potential sensing system has been introduced by the use of gramicidin, a 
statistically opening antibiotic pentadecapeptide channel [6]. The challenge for the use of large 
membrane proteins immobilized on surfaces is to control their orientation (the binding site of a 
receptor needs to be accessible for the analyte). Antibodies will play a major role for the proper 
alignment in the future [7]. Optical spectroscopy (fluorescence) has been used to detect the activity of 
a surface immobilized 5-HT3 serotonine receptor [8]. Investigations are also being undertaken to 
study a suitable polymer support material for immobilization of the ion channels. It has been shown 
that polyimides can be covered with a lipid membrane ready for the use with micro chip devices [9]. 
 
Measurements with alamethicin, a channel forming peptide antibiotic, and the nAChR showed that 
the membrane was stable for ca. 50 hours. 3-Mercaptopropionic acid [10] and porous layers of 
polyethylene terephtalate (PET) [11] also seem to be suitable materials for coating with ion channel 
containing lipid bilayers . 
Membrane proteins in general, and ion channels in particular, are difficult to express in large amounts 
suitable for e.g. structural and functional studies. This might be a bottleneck for the large-scale 
production of biosensors. An alternative route could be the use of fragments of the complete 
membrane protein (peptides). Fragments of Na+ and K+ channel have been immobilized on gold 
surfaces and used to detect an analyte [12, 13]. Another potential segment for the use in sensor 
devices is the TM segment responsible for the ion flow in the channel protein. For the TM segment of 
the nAChR it has been proved that this segment exhibits channel activity similar to the full length 
nAChR [14]. Usually the length of a TM segment does not exceed 30 amino acids, which means that 
peptides can easily be obtained by solid phase peptide synthesis or adjusted expression systems. As 
a case study for such investigations we use ion channel forming membrane proteins from viruses.   
Three small auxiliary proteins, all of around 100 amino acids in length, coded for by different types of 
influenza virus are called: M2 (influenza A), NB (influenza B), and CM2 (influenza C) (Fischer & 
Sansom; Viral ion channels: Structure and function, review in Biochim. Biophys. Acta - Membranes, 
accepted 2001). A similar short protein, Vpu, is found in the genome of the human immunodeficiency 
virus type-1 (HIV-1) (Retroviridae). Ion channel activity is confirmed for M2, NB, and Vpu. Recently it 
has been found that the plant virus Paramecium bursaria chlorella virus (PBCV-1) encodes an ion 
channel which resembles a miniaturised K+-channel [15]. In all cases the short proteins have to 
assemble to form functional channels. Solution and solid state nuclear magnetic resonance (NMR) 
[16-21], Fourier transform infrared (FTIR) [21-24], and circular dichroism (CD) [17,25,26] 
spectroscopy have now been used to resolve the structure of the influenza and HIV-1 ion channel 
proteins. We have also previously studied the putative single TM segment of the viral ion channel 
proteins by computational methods [27].  
NB from influenza B is 100 amino acids long. The first 18 residues of NB from influenza B are located 
at the extramembraneous side (N-terminal). Ca. 22 residues span the membrane leaving ca. 60 
residues on the C-terminal end [28, 29]. NB is expressed at the surface of the virion with its N-
terminal site facing the outside of the capsule and its C-terminus the inside [30].  NB is exposed to the 
cytoplasm in infected cells [30-33]. By analogy with the M2 protein of influenza A, it is suggested that 
NB is a channel-forming protein. Conductance measurements with purified NB expressed in 
Escherichia coli and reconstituted in lipid bilayers reveal channel activity [33]. Depending on the 
experimental conditions (e.g. salt concentration, pH) NB-induced channels in transfected mouse 
erythroleukemia (MEL) cells exhibit selectivity for Na+, Cl-, and H+ ions [34]. Thus, as emphasized by 
Lamb and Pinto [35], it is important to firmly establish that NB is a channel protein, and that its 
channel inducing activity is not simply due to resolution of endogenous channels. To this end we have 
shown that synthetic peptide corresponding to the transmembrane helix of NB self-assembles to form 
ion channels in lipid bilayers [26]. 
Until recently the only anti viral drug available was amantadine (amantadine-1) and its structural 
analogous rimantadine (α-methyl-1-adamantanemeth-anamine) [36,37]. Amantadine is applied to 
infections caused especially by influenza A. Its use results in side effects on the central nervous 
system [38]. Side effects are also found, to a lesser extent, for the application of rimantadine [39]. 
Amantadine is used for a preventive therapy and also during an already ongoing infection with 
influenza A. Amantadine selectively blocks the viral ion channel protein M2. This molecule and its 
derivatives have also been investigated as possible drugs effective against HIV-1 [40]. 
The model of M2 channel blocking by amantadine is that the molecule enters the pore and prohibits 
an ion flux [41]. It has been shown that the sensitivity to amantadine is affected by mutations of 
residues Val-27, Ala-30, and Ser-31 which are located within the putative lipid membrane spanning 
TM region of M2 [42]. Investigations using neutron diffraction data are in support of the loci for 
amantadine – M2-channel interaction being between Val-27 and Ser-31 [43]. Experiments with M2 
expressed in oocytes of Xenopus laevis and whole cell current recordings show that concentrations 
between 1 and 100 µM amantadine have an effect on channel activity of M2. Sensitivity is different 
between the individual virus strains (Udorn > Weybridge > Rostock) and is due to mutations in the TM 
region of the protein. Synthetic peptides analogous to the TM region of M2 lose channel activity in the 













Experiments with amantadine have been performed with NB expressed in Escherichia coli, purified 
and reconstituted in a lipid membrane. Amantadine concentrations of 2 - 3 mM lead to reduced 
channel activity [33]. The drug lowers the current amplitude and its frequency.  
A
Fig. 2: Bilayer set up used for 
channel recordings. The lipids are 
put onto an aqueous subphase 
(blue) in both sides of the chamber 
and raised to cover a small aperture 
in a Teflon film (thick black bars 
between the two chambers). Inserted 
ion channels (red) allow the ion flux 
(arrow) which can be registered with 
the electrodes. The left electrode is 
connected to the amplifier (A). This 
side is called the cis side in this 
study. The other chamber is 
grounded and called trans side. 
 
We have synthesised the putative TM region of NB proposed by a computational study on the single 
strand embedded in a hydrated lipid bilayer [27]: Ile-Arg-Gly-Ser20-Ile-Ile-Ile-Thr-Ile-Cys-Val-Ser-Leu-
Ile30-Val-Ile-Leu-Ile-Val-Phe-Gly-Tyr-Ile-Ala40-Lys-Ile-Phe-Ile (NB, Lee, with Cys-38 replaced by Tyr 
(bold); sequence using the single letter code: IRGS20 IIITICVSLI30 VILIVFGCIA40 KIFI). The TM region 
exhibits channel activity [26]. In the present study we address the sensitivity of the TM segment of NB 
to amantadine when reconstituted into a lipid bilayer. Amantadine is added with increasing 
concentration to the lipid bilayer containing the TM segments of NB [45]. The outcome of this work is 
interpreted in terms of a possible use of these systems in biosensors. 
 
Materials and Methods 
Peptide synthesis: 
The transmembrane segment of NB (IRG S20 IIITICVSL I30 VILIVFGYI A40 KIFI; NB, Lee) was 
synthesised using standard Fmoc methodology on an Applied Biosystems 430A Automated Peptide 
Synthesiser. Peptide acid linker (PAC) – poythylene glycole (PEG) – polystyrene (PS) resin (4-
hydroxymethyl-phenoxyacatic acid attached to polyethylene glycol-polystyrene (MBHA) graft support) 
and HATU (N-[(dimethylamino)-1H-1,2,3-triazolo[4,5-b]pyridino-1-ylmethylene]-N-
methylmethanaminium hexafluorophosphate N-oxide) coupling reagent purchased from PE 
Biosystems were used. For a detailed description see Fischer et al. 2000 [26]. The peptide was 
purified by preparative HPLC using a POROS RP 4.6 x 100 mm column at a flow rate of 5 ml/min. 
The buffers used were: A = water (0.1 % TFA (trifluoroacetic acid)) and B = acetonitrile (0.1 % TFA). 
A gradient was run between 5% and 50 % B over 20 min. Matrix assisted laser desorption ionisation - 
time of flight spectrometry (MALDI-TOF) was done on a Micromass TofSpec 2E mass spectrometer 
operating in the linear mode from an α-cyano-4-hydroxycinnamic acid matrix. For automated amino 
acid sequence determination samples were adsorbed onto PVDF membrane (polyvinylidene 
diflouride - 0.2 µm porosity) using a ProSorb cartige (PE Biosystems, Warrington, UK) and the 
manufacturer’s protocol was followed. The membrane-bound samples were then excised from the 
ProSorb cartridge and N-terminally sequenced on an Applied Biosystems 494A "Procise" sequencer 
(PE Biosystems, Warrington, UK). 
Channel recordings in planar lipid bilayers: 
Planar lipid bilayers were formed across an aperture (ca. 100 µm diameter) in a thin (25 µm) teflon 
film (Yellow Springs Instruments, OH, USA) [46] (Fig. 2). 40 µl of lipid (10 : 1 (w/w) L-α-
phosphatidylcholine (Type II-s) and cholesterol, both from Sigma) in pentane were spread on top of a 
buffer (0.5 M KCl, 10 mM BES (N,N-bis(2-hydroxyethyl)-2-aminoethane-sulfonic acid), pH 7.0) which 
was raised across the aperture. After adding the protein (dissolved in methanol) on the cis side 
(amplifier) the bilayer was formed by raising the buffer level. Amantadine (Adamantan-1-amine 
hydrochloride, Sigma, UK) was added to the trans side (ground) in subsequent amounts to reach the 
final concentration prior to the recording.  Electrical currents were measured with an Axopatch 1D 
amplifier at a rate of 5 kHz and filtered with 1 kHz using a Digi Data 1200 interface (Axon Instruments, 
CA, USA). Currents were generated using a Function Generator TG 302, LEVELL, Barnet, UK. For 
data analysis Origin 5.0 was used.  
 
Results 
The upper trace of Fig. 3,I shows recordings of NB peptide reconstituted in lipid bilayers at an applied 
transmembrane potential of -100 mV without the presence of amantadine. Analysis of the data 
reveals approximately 4 conductance levels of ca. 20, 95, 230 and 330 pS (see also [26]). 
Amantadine is added on the trans side of the membrane. Applying a transmembrane voltage of cis –
100 mV pulls the trans amantadine towards the lipid bilayer. At a concentration of 0.02 mM 
amantadine the channel activity remains unchanged. Levels of 20 and 140 pS are observed. With 
increasing amantadine concentration conductance levels of 130 pS (0.04 mM), 230 pS (0.06 mM), 
and 270 pS (0.08 mM) are found. The open time of the events seem to be extended over several 
seconds. At amantadine levels of 0.06 and 0.08 mM the open periods are interrupted by short periods 
of channel inactivity. Channel inactivity increases with increasing drug concentration. At 0.1 mM 
amantadine channel activity is completely abolished. Addition of amantadine is continued until a final 
concentration of 2.1 mM (Fig. 3,II). Between 0.1 and 2.1 mM amantadine events of channel activity 
are only observed occasionally, e.g. at 0.7 and 0.9 mM amantadine with conductance of around 5 pS. 
Fitting the current integrated over time from each trace in Fig. 3 with a sigmoidal dose-response curve 
allows an estimate of the binding constant to be Kapp = 0.08 ± 0.01 mM.  
To address the question of whether amantadine-induced blockage of channel activity is voltage 
dependent we applied +100 mV in the presence of 2.1 mM amantadine (Fig. 4,I). After several 
seconds channel activity is restored. The current profile is identical with the profile at -100 mV. 
Subsequent reversal, as shown in Fig. 4,I allows the ion flux only for a few seconds before recordings 
return back to the zero-line (lower trace in Fig. 4,I). This experiment could be repeated several times. 
In the presence of 4.1 mM amantadine (Fig. 4,II) channel activity is blocked at -100 mV 
transmembrane potential. The reversed potential of +100 mV does not lead to any restoration of 
channel activity. Voltage as high as +170 mV is necessary to induce an ion flux (data not shown). 
From these data we conclude that channel inactivity is reversible and controlled by amantadine 











































Fig. 3: Ion channel activity of NB at –100 mV. Amantadine is added from a stock solution of 200 fold 
excess in such a way, that on the trans side the final concentration as outlined is reached. I: (scaling 
is 100 pS and 10s) channel activity without amantadine (upper trace), and in the presence of 
amantadine of 0.02 – 0.1 mM (following traces). Black lines represent the main conductance stages: 
20, 100, 230, und 330 pS (0 mM amantadine); 140 pS (0.02 mM amantadine), 125 pS (0.04 mM 
amantadine); 230 pS (0.06 and 0.08 mM amantadine). II: Recording with 0.1  – 2.1 mM amantadine: 
5 pS (0.7 and 0.9 mM amantadine). Please note the change in scaling (25 pS and 10s) compared to I 
(100 pS and 10s).  
 
Discussion 
Channel activity of the TM segment of NB can be blocked by the antiviral drug amantadine with an 
approximate binding constant Kapp = 0.08 mM. Channel behaviour of the TM segment is comparable 
to the behaviour of the complete protein in the presence of amantadine. For M2 of influenza A it has 
been reported that channel activity of the TM segment incorporated into planar lipid bilayers can be 
reversibly blocked by amantadine [44]. In the case of the fully transcribed M2 protein and 
reconstitution into a planar lipid bilayer the presence of amantadine reduces the channel opening 
[47].  For Vpu it has been demonstrated that the synthetic TM segment of the Vpu protein 
reconstituted in a planar lipid bilayer shows similar channel activity and ion selectivity to the complete 
channel protein [48]. Sensitivity of the segment to amantadine has not yet been reported. However, it 
is striking that in the case of viral ion channel proteins in general, simply the TM segments reflect the 
behaviour of the complete channel.  
A possible explanation, which is compatible with our results, is that amantadine interacts via 
integration in the hydrophobic phase of the lipid bilayer and subsequent attachment to the helical 










Similar rotational / screw like motions are suggested for other short and complex ion channels [49-
53]. However, such motions could also be blocked if amantadine penetrates into the pore. 
Amantadine by itself does not perturb the bilayer according to neutron diffraction data (Duff et al. 
1994 [43]). Once channel activity is blocked the peptide containing membrane does not show any 
current leakage up to ca. 4.1 mM amantadine (data not shown). This would suggest that channel 
blocking through distortion of the bilayer, with the consequence of disabling the peptide to assemble, 
might be ruled out. However, electrophysiological data indicate that rimantadine:- a derivative of 
amantadine - changes the dynamics of artificial lipid bilayers [54]. The presence of rimantadine leads 
either to a ‘rigidification’ or ‘fluidization’ of an artificial lipid membrane in dependence of lipid 
composition. Rimantadine leads also to an increased aggregation of erythrocytes. These data 
suggest that any membrane protein might be affected by the altered fluidity of the lipid membranes 
caused by the drug. Rimantadine penetrates through the lipid membrane if given only to one side of 







The excess of rimantadine on one side of the 
membrane and the increasing pH difference 
between the two sides alters the membrane 
potential. This could affect the conductance 
behaviour of membrane-embedded pore forming 
proteins such as e.g. NB. As a conclusion, future 
measurements have to address indirect affects 
such as (i) altered membrane potential or (ii) 
fluidity of the membrane on the pore blocking behaviour of amantadine and its derivatives on NB. 
Corresponding effects of amantadine, as those mentioned for NB peptide, were not seen with the 
channel forming peptide alamethicin (data not shown). This suggests that channel block is due to 
specific interaction of amantadine with the NB peptide.  
Conclusion 
The TM segment of NB is sensitive to the anti viral drug amantadine. Concentrations of amantadine 
down to 0.04 – 0.1 mM are detectable because of a change in the channel behaviour of the peptide 
induced by amantadine. We find changes in the frequency, duration and amplitude of the current. 
This is in accordance with findings for the whole protein. The TM segment represents the behaviour 
Fig. 3: NB peptide in the presence of 2.1 mM 
(I) and 4.1 mM (II) amantadine. Applied 
potentials of +100 and –100 mV. Second 
curves in I and II are recorded ca. 1 min after
recording of the upper curves. 
of the whole protein in this respect. Amantadine shows reversible blocking of the channel formed by 
the TM segments of NB.  
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